Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modern Molecular Taxonomy01:29

Modern Molecular Taxonomy

519
Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...
519

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changing standard of care during a randomized trial: examples, considerations and guidelines.

Journal of the National Cancer Institute·2026
Same author

Molecular Profiling for Precision Oncology: Moving Beyond Feasibility and Safety.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A note on rank-preserving structural failure time models to account for crossover.

Clinical trials (London, England)·2026
Same author

Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.

Cancer chemotherapy and pharmacology·2025
Same author

p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2<sup>+</sup> breast cancer that limits trastuzumab deruxtecan efficacy.

Nature cancer·2025

Related Experiment Video

Updated: Jan 1, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K

Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?

Boris Freidlin1, Carmen J Allegra2,3, Edward L Korn1

  • 1Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 9609 Medical Center Dr, Bethesda, MD 20892, USA.

Journal of the National Cancer Institute
|December 24, 2019
PubMed
Summary

Molecular profiling (MP) guides cancer treatment, but evidence for its clinical benefit is challenging to obtain. A proposed two-step strategy uses multibasket trials followed by randomized trials to rigorously identify effective mutation-agent pairs for routine clinical practice.

More Related Videos

Methylation Specific Multiplex Droplet PCR using Polymer Droplet Generator Device for Hematological Diagnostics
09:05

Methylation Specific Multiplex Droplet PCR using Polymer Droplet Generator Device for Hematological Diagnostics

Published on: June 29, 2020

5.6K
High Throughput MicroRNA Profiling: Optimized Multiplex qRT-PCR at Nanoliter Scale on the Fluidigm Dynamic ArrayTM IFCs
07:27

High Throughput MicroRNA Profiling: Optimized Multiplex qRT-PCR at Nanoliter Scale on the Fluidigm Dynamic ArrayTM IFCs

Published on: August 3, 2011

21.0K

Related Experiment Videos

Last Updated: Jan 1, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K
Methylation Specific Multiplex Droplet PCR using Polymer Droplet Generator Device for Hematological Diagnostics
09:05

Methylation Specific Multiplex Droplet PCR using Polymer Droplet Generator Device for Hematological Diagnostics

Published on: June 29, 2020

5.6K
High Throughput MicroRNA Profiling: Optimized Multiplex qRT-PCR at Nanoliter Scale on the Fluidigm Dynamic ArrayTM IFCs
07:27

High Throughput MicroRNA Profiling: Optimized Multiplex qRT-PCR at Nanoliter Scale on the Fluidigm Dynamic ArrayTM IFCs

Published on: August 3, 2011

21.0K

Area of Science:

  • Oncology
  • Genomics
  • Clinical Trial Design

Background:

  • Molecular profiling (MP) aims to personalize cancer treatment by matching patients to targeted therapies, potentially improving outcomes and reducing toxicity.
  • Current development of MP panels often relies on non-standardized algorithms and non-randomized data, hindering the establishment of clinical utility.
  • Interpreting evidence from non-randomized studies, PFS ratios, and multibasket trials presents challenges in demonstrating the real-world benefit of MP-guided treatment.

Observation:

  • Non-randomized studies comparing MP-guided therapy to standard of care (SOC) have limitations in establishing causality.
  • Progression-free survival (PFS) ratios, comparing MP-directed treatment to prior SOC, can be confounded by patient selection and disease heterogeneity.
  • Multibasket trials assess targeted therapy efficacy in specific molecular subgroups but may not reflect real-world clinical practice across diverse histologies.

Findings:

  • A novel two-step strategy is proposed to rigorously evaluate mutation-agent pairs for targeted cancer therapy.
  • Step 1 involves using multibasket trials to identify promising mutation-agent pairs based on activity in molecularly defined subpopulations.
  • Step 2 utilizes a randomized clinical trial design to test molecular panels, guided by identified mutation-agent pairs, against SOC.

Implications:

  • This evidence-based, two-step approach aims to overcome limitations in current MP panel development.
  • It facilitates the rigorous identification and validation of mutation-agent pairs suitable for routine clinical implementation.
  • The proposed strategy can accelerate the translation of molecular profiling into improved patient care and treatment outcomes in oncology.